Can You Die From Myelofibrosis? Prognosis and Life Expectancy

Myelofibrosis is a life-threatening blood cancer, and yes, it can be fatal. The disease progressively scars the bone marrow, disrupts blood cell production, and opens the door to complications that range from severe anemia to transformation into acute leukemia. Median survival across large studies has historically ranged from roughly four and a half to six and a half years from diagnosis, though newer treatments have pushed that number higher for many patients. The range of individual outcomes is enormous, shaped by genetics, risk category, age, and how the disease responds to therapy.

How Myelofibrosis Shortens Life

Large international studies have tracked survival in myelofibrosis over several decades. One landmark analysis found that median survival rose from about four and a half years among patients diagnosed between 1980 and 1995 to roughly six and a half years for those diagnosed between 1996 and 2007, reflecting improvements in supportive care and disease management over that window.¹ A more recent single-center study reported a median overall survival of about 54 months across its entire patient cohort.²

A Swedish population-based study put the survival gap in starker terms: patients with primary myelofibrosis lost an average of about four and a half years of life expectancy compared to matched members of the general population. That loss was considerably larger than for the other myeloproliferative neoplasms, where patients with polycythemia vera lost roughly two years and those with essential thrombocythemia lost about one and a half years on average.³ These numbers are averages. Some patients live well over a decade with relatively indolent disease, while others with aggressive forms survive fewer than two years.

What People With Myelofibrosis Actually Die From

Myelofibrosis does not typically kill through a single mechanism. Instead, the progressive failure of normal bone marrow function creates several pathways to serious, sometimes fatal complications. The most commonly cited fatal outcomes include transformation to acute leukemia, blood clotting or bleeding events, organ failure, and infections.⁴

Leukemic Transformation

One of the most feared turns in myelofibrosis is its progression to acute myeloid leukemia. Among the myeloproliferative neoplasms, primary myelofibrosis carries the highest risk for this, with roughly 10 to 20 percent of patients transforming in the first ten years of disease.⁵ Once leukemia develops, outcomes are poor. Patients with bone marrow blast counts above 10 percent or certain high-risk chromosomal changes had a median survival of just 10 months and a one-year leukemia transformation rate of 13 percent, compared to only about 2 percent for patients lacking those risk factors.⁶ Leukemia arising from myelofibrosis tends to respond poorly to standard chemotherapy regimens, making it substantially harder to treat than leukemia that develops on its own.

Vascular Complications

Blood vessel problems are a major and sometimes underappreciated killer. A Swedish population-based study found that vascular complications were the leading cause of death in myelofibrosis patients, and that patients who experienced these events had a median survival of 48 months, compared to 92 months for those who did not.⁷ These complications span a wide range: deep vein thrombosis, pulmonary embolism, stroke, heart attack, and unusual clots in the portal vein or other abdominal vessels. Myelofibrosis predisposes people to clots in the portal vein system, which can lead to a form of high blood pressure in the liver’s circulation and, in some cases, dangerous bleeding from swollen veins in the esophagus.⁸

Infections

As the bone marrow becomes increasingly scarred, its ability to produce functioning white blood cells declines, leaving patients vulnerable to infections. In a study of over 500 myelofibrosis patients, about 22 percent experienced at least one infection during follow-up, most commonly bacterial pneumonia. Infections were the direct cause of death in about 7 percent of patients who died during the study period.⁹ The cumulative risk rises over time: roughly 20 percent of patients had experienced an infection by five years, a third by ten years, and over half by twenty years.

Extramedullary Hematopoiesis and Organ Damage

When the bone marrow can no longer produce enough blood cells, the body sometimes compensates by shifting blood cell production to other organs, primarily the spleen and liver, and occasionally the lungs. This process, called extramedullary hematopoiesis, can cause massive spleen enlargement that crowds the abdomen, causes pain, and worsens blood counts. In the lungs, it can contribute to pulmonary hypertension and respiratory failure, both of which carry serious mortality risk, particularly in patients undergoing stem cell transplant.¹⁰

How Doctors Estimate Individual Prognosis

Not every myelofibrosis patient faces the same timeline. Oncologists use scoring systems to sort patients into risk categories, which helps guide treatment decisions and gives patients a clearer picture of what they are facing. The most widely used tool is the Dynamic International Prognostic Scoring System, known as DIPSS. It evaluates five factors: age over 65, constitutional symptoms like fevers, night sweats, and weight loss, hemoglobin below a certain threshold, elevated white blood cell count, and the presence of immature blood cells called blasts in the bloodstream.¹¹

The difference between risk groups is dramatic. In one study with a median follow-up of nearly six years, patients in the low-risk and intermediate-1 categories had such favorable outcomes that the median survival had not yet been reached. Patients in the intermediate-2 group had a median survival of about seven years, and those in the high-risk group survived a median of just two and a half years.¹² The key advantage of the DIPSS over earlier scoring tools is that it can be recalculated at any point during follow-up, not just at diagnosis, allowing risk estimates to be updated as the disease evolves.

Why Genetics Can Change the Entire Picture

Clinical scoring systems like DIPSS capture only part of the story. Genetic mutations play a powerful and sometimes decisive role in determining how quickly myelofibrosis progresses. The three main “driver” mutations found in myelofibrosis are JAK2, CALR, and MPL. Among these, one specific subtype of CALR mutation, known as type 1 or type 1-like, consistently predicts the best outcomes. Patients with this mutation lived significantly longer than those with JAK2, MPL, or other CALR variants, and they fared better even when they also carried additional harmful mutations.¹³

Beyond driver mutations, additional so-called “non-driver” mutations in genes like ASXL1, SRSF2, EZH2, and IDH1/2 can sharply worsen the outlook. An international study of nearly 800 patients found that those with no detrimental mutations had a median survival of about 12 years, those with one mutation survived roughly 7 years, and those with two or more mutations had a median survival of only about two and a half years. The number of harmful mutations also predicted the risk of transformation to leukemia.¹⁴ The presence of type 1-like CALR mutations partially offset the bad effects of high-risk mutations like ASXL1 and SRSF2, extending median survival from roughly three years to nearly six years even in that high-risk genetic context.¹³

The growing recognition that genetics matter as much as clinical features has pushed oncologists toward integrating molecular data into risk scoring. Current research focuses on combining genetic profiles with clinical risk scores to produce more personalized prognoses.¹⁵

Treatments That Can Extend Survival

Myelofibrosis has only one established cure: an allogeneic stem cell transplant, which replaces the diseased bone marrow with healthy donor cells. That curative potential comes with serious trade-offs. The procedure carries a high risk of treatment-related death and graft failure, meaning the transplanted cells sometimes fail to take hold.¹⁶ As a result, transplant is generally reserved for younger, fitter patients in higher-risk categories where the survival benefit outweighs the procedural danger. Pre-transplant DIPSS classification strongly predicts how well the transplant goes: high-risk patients had about a fourfold greater risk of death after transplant compared to low-risk patients.¹²

For the majority of patients who are not transplant candidates, the arrival of ruxolitinib in the early 2010s was a meaningful advance. Pooled data from two large randomized trials showed that patients receiving ruxolitinib had a median overall survival of about five and a third years, compared to roughly three and a half to four years for those receiving either placebo or best available conventional therapy. The risk of death was reduced by about 30 percent.¹⁷ After adjusting for the fact that many patients in the control group eventually crossed over to ruxolitinib, the survival advantage was even more pronounced.¹⁸ Ruxolitinib does not cure the disease, but it effectively controls symptoms like spleen enlargement, night sweats, and bone pain, and its survival benefit holds regardless of whether a patient is anemic at the start of treatment.

Newer JAK inhibitors and combination therapies are now in various stages of testing. The treatment landscape continues to evolve, but ruxolitinib remains the backbone of drug therapy for intermediate- and high-risk patients.

Anemia and Transfusion Dependence as Red Flags

Anemia, meaning a hemoglobin level too low to deliver adequate oxygen to the body’s tissues, is one of the most common symptoms of myelofibrosis and one of the clearest markers of a worsening prognosis. Some patients eventually become transfusion-dependent, needing regular red blood cell transfusions to maintain a functional hemoglobin level. This transition matters for more than quality of life. A study of 288 patients with primary myelofibrosis found that being transfusion-dependent at diagnosis predicted shorter survival independently of the IPSS risk score.¹⁹

A large systematic review reinforced this pattern, finding across 23 studies that both anemia and transfusion dependence were associated with shortened overall survival. The hazard ratios in these studies ranged widely, but the direction was consistent: more severe anemia and greater reliance on transfusions tracked with worse outcomes.²⁰ This is why treating anemia, whether through drugs like luspatercept, danazol, or erythropoiesis-stimulating agents, has become a focus of clinical trials alongside the JAK inhibitors.

Primary Versus Secondary Myelofibrosis

Myelofibrosis can arise on its own, which is called primary myelofibrosis, or it can develop as a late complication of two related blood disorders: polycythemia vera or essential thrombocythemia. These latter forms are grouped as secondary myelofibrosis. The question of whether primary and secondary types carry different prognoses is not fully settled, but molecular studies have shown real differences between the two. Primary myelofibrosis tends to harbor more of the high-risk mutations, particularly ASXL1 and SRSF2, than secondary myelofibrosis does.²¹ Specific mutations like SRSF2 and TP53 were strongly associated with worse survival in primary myelofibrosis, while ASXL1 and TP53 had similar effects in the secondary form. In practical terms, secondary myelofibrosis patients have often already been followed for years by a hematologist for their preceding condition, which can mean earlier detection of fibrotic changes. The prognostic scoring systems were originally developed for primary myelofibrosis, and applying them to secondary cases requires some caution.

How Comorbidities Reshape the Outlook

Because myelofibrosis is most commonly diagnosed in people over 60, many patients arrive with other health conditions already in progress: cardiovascular disease, diabetes, chronic kidney disease, prior cancers. These comorbidities independently affect survival and can sometimes matter as much as the myelofibrosis itself. A study of 131 patients found that when comorbidity severity was added to the standard prognostic score, the resulting model did a better job of separating patients into distinct survival groups. In one analysis, patients in the combined high-risk category (high IPSS score plus severe comorbidities plus advanced bone marrow fibrosis) had a median survival of only 22 months, while those in the low-risk category had not yet reached their median survival.²²

Interestingly, the impact of comorbidities may not be uniform across age groups. One analysis found that existing health conditions had a greater negative impact on survival in patients younger than 65 than in older patients.²³ The likely reason is that younger patients are generally expected to have long survival with myelofibrosis, so adding serious comorbidities disproportionately narrows their advantage. For older patients, who already face shorter expected survival from both age and the disease, comorbidities add less relative weight.

When Palliative Care Enters the Picture

Myelofibrosis occupies an awkward space in cancer care. It is chronic rather than immediately life-threatening for many patients, but it can accelerate unpredictably, especially if it transforms into leukemia or if complications stack up. This unpredictability may explain a troubling pattern in how end-of-life care is handled. A retrospective study of patients with hematologic cancers, including myelofibrosis, found that while about three-quarters were eventually referred to palliative care before death, the timing of those referrals was strikingly late. Almost three-quarters of referred patients first saw a palliative care team in the final 30 days of life, and one-third were not referred until the last 5 days. The median time from referral to death was just 13 days.²⁴

That gap matters because palliative care is not just about dying. It focuses on symptom management, quality of life, and helping patients and families make informed decisions throughout the disease course. Myelofibrosis in particular causes symptoms like severe fatigue, bone pain, abdominal discomfort from an enlarged spleen, and the psychological burden of a chronic cancer with uncertain trajectory. Patients who receive earlier palliative care referrals, even years before end of life, tend to report better symptom control. The evidence suggests that the biggest gap in myelofibrosis care is not a lack of available treatments but a delay in connecting patients with the support systems that improve the experience of living with the disease, not just the length of it.